The UK published updated information for the life sciences sector in the event of a “no deal” Brexit, which included a second letter to industry on converting community marketing authorizations (CMAs) to UK Marketing Authorizations (Mas) – or so- called ‘grandfathering’ – and information for businesses supplying medicines and medical devices on what to expect on day one of a “no deal’ scenario. Some contingency plans by the UK to stockpile medicines to mitigate the effects of a “no-deal” Brexit consist of contract agreements, which “will cover additional capacity including 53,000 pallets of ambient storage, 5,000 pallets of refrigerated storage and 850 pallets of controlled drug storage,” writes Minister of State Stephen Hammond from the Department of Health and Social Care.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
